Detailed Review Of Prospects For Adamis Pharmaceuticals Corporation Stock

Adamis Pharmaceuticals Corporation [ADMP] stock is trading at $0.33, up down -1.53%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ADMP shares have gain 0.77% over the last week, with a monthly amount drifted -13.90%, and not seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

On 12, August 2022, Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders. In a post published today on Yahoo Finance, Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022.

From an analyst’s perspective:

Adamis Pharmaceuticals Corporation [NASDAQ: ADMP] stock has seen the most recent analyst activity on May 13, 2020, when Maxim Group upgraded its rating to a Buy but kept the price target unchanged to $1.50 for it. Previously, Dawson James downgraded its rating to Neutral on February 27, 2020. On November 26, 2019, downgrade downgraded it’s rating to Mkt Perform. B. Riley FBR downgraded its rating to a Sell and decreased its price target to $1.10 on July 16, 2019. B. Riley FBR downgraded its rating to a Neutral and reduced its price target to $2.50 on November 12, 2018. Maxim Group reiterated a Buy rating for this stock on May 11, 2018, and upped its price target to $10. In a note dated March 23, 2018, B. Riley FBR Inc. reiterated an Buy rating on this stock and boosted its target price from $6.25 to $7.50.

Adamis Pharmaceuticals Corporation [ADMP] stock has fluctuated between $0.31 and $1.48 over the past year. Currently, Wall Street analysts expect the stock to reach $1.50 within the next 12 months. Adamis Pharmaceuticals Corporation [NASDAQ: ADMP] shares were valued at $0.33 at the most recent close of the market. An investor can expect a potential return of 354.55% based on the average price forecast.

Analyzing the ADMP fundamentals

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.3225 points at the first support level, and at 0.3171 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.3351, and for the 2nd resistance point, it is at 0.3423.

Adamis Pharmaceuticals Corporation [ADMP] reported earnings per share of -$0.07 for its fiscal quarter that ended on 3/30/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.03/share, meaning a difference of $-0.04 and a surprise factor of -133.30%. By comparison, the stated earnings for the previous quarter ended on 12/30/2021 were -$0.06 per share as compared to estimates of -$0.04 per share, a difference of $-0.02 representing a surprise of -50.00%.

Ratios To Look Out For

For context, Adamis Pharmaceuticals Corporation’s Current Ratio is 1.60.

Transactions by insiders

Insider trading has also been a hot topic recently, with 0 insiders purchasing 0 shares and 0 selling 0 shares in the past 3 months. Recent insider trading involved Moss Ronald B., Chief Medical Officer, that happened on Mar 18 when 8199.0 shares were sold. SVP and Chief Business Officer, Marguglio David J. completed a deal on Mar 18 to sell 11859.0 shares. Meanwhile, President & CEO CARLO DENNIS J PHD sold 10490.0 shares on Mar 18.